Core Viewpoint - Company Kefu Medical has submitted an application for a dual listing on the Hong Kong Stock Exchange, marking its entry into the A+H market while facing challenges in profitability despite strong online sales performance [1][5]. Group 1: Company Overview - Kefu Medical, established in 2007, focuses on home medical devices and is one of the largest companies in this sector in China, ranking second in sales among home medical device companies as of 2024 [1][2]. - The company has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America [1]. Group 2: Financial Performance - Kefu Medical's revenue for the years 2022 to 2025 (first half) is approximately 2.977 billion, 2.854 billion, 2.983 billion, and 1.496 billion yuan respectively, with a compound annual growth rate of 2.9% [2]. - The net profit for the same periods is approximately 302 million, 253 million, 312 million, and 167 million yuan, indicating a significant decline in profitability in 2023 and a further 9.5% decrease in the first half of 2025 [2]. Group 3: Market Position and Strategy - Kefu Medical has achieved significant online sales, with 2024 online sales reaching 1.981 billion yuan, ranking second among Chinese home medical device companies [4]. - The company has a strong presence on major e-commerce platforms, with numerous products ranking highly in sales across platforms like Douyin, Tmall, and JD [4]. - Kefu Medical is in the early stages of developing its overseas business, with foreign revenue accounting for only 1.98% of total revenue in 2024, but showing a notable growth of over 200% in the first half of 2025 [4]. Group 4: Future Plans - The funds raised from the Hong Kong listing will primarily be used for product research and development, global sales network expansion, business development, and brand marketing [5].
可孚医疗要去港股，净利下滑！